ZURICH, May 15 (Reuters) - Novartis on Monday
named the intended new board members of Sandoz, the generics
business it plans to spin off to shareholders later this year.
The Basel company approved the recommendations of Sandoz
Chairman-designate Gilbert Ghostine for the 10 members of the
board, which will start preparatory work in June.
The new members include Francois-Xavier Roger, currently CFO
at Nestle , Urs Riedener, former CEO of dairy group Emmi and Shamiram Feinglass, who has worked as Chief Medical
Officer for Life Sciences at medical technology company Danaher .
Others to be appointed to the board include former Novartis
executive Karen Huebscher, Aarti Shah, who worked at Eli Lilly , and Deutsche Lufthansa CFO Remco Steenburgen.
Unilever Chief Legal Officer Maria Varsellona, and
former Procter & Gamble executive Yannis Skoufalos,
complete the nominations to the committee.
"The Sandoz Board of Directors will start preparatory work
from June onwards and will be effective following the planned
spin-off of Sandoz in the second half of 2023, subject to
Novartis Board of Directors and shareholder approval," Novartis
said on Monday.
(Reporting by John Revill; editing by Uttaresh Venkateshwaran)
Messaging: john.revill.thomsonreuters.com@reuters.net))
Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.